Skip to main content
SpringerLink
Log in

Power and Sample Size

  • Living reference work entry
  • First Online:
Principles and Practice of Clinical Trials

  • 466 Accesses

Abstract

A critical component of clinical trial design is determining the appropriate sample size. Because clinical trials are planned in advance and require substantial resources per patient, the number of patients to be enrolled can be selected to ensure that enough patients are enrolled to adequately address the research objectives and that unnecessary resources are not spent by enrolling too many patients. The most common approach for determining the optimal sample size in clinical trials is power calculation. Approaches for power calculations depend on trial characteristics, including the type of outcome measure and the number of treatment groups. Practical considerations such as trial budget, accrual rates, and drop-out rates also affect the study team’s plan for determining the planned sample size for a trial. These aspects of sample size determination are discussed in addition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Brookmeyer R, Crowley JJ (1982) A confidence interval for the median survival time. Biometrics 38:29–41

    Article  Google Scholar 

  • Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE (2014) American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32(12):1277–1280

    Article  Google Scholar 

  • Lee JJ, Chu CT (2012) Bayesian clinical trials in action. Stat Med 31(25):2955–2972

    Article  MathSciNet  Google Scholar 

  • Simon R (1989) Optimal two-stage designs. Control Clin Trials 10:1–10

    Article  Google Scholar 

  • Sobrero A, Bruzzi P (2009) Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 27(35):5868–5873

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. American Society of Clinical Oncology, Alexandria, VA, USA

    Elizabeth Garrett-Mayer

Authors
  1. Elizabeth Garrett-Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Garrett-Mayer .

Editor information

Editors and Affiliations

  1. Samuel Oschin Comprehensive Cancer Insti, WEST HOLLYWOOD, CA, USA

    Steven Piantadosi

  2. Bloomberg School of Public Health, Johns Hopkins Center for Clinical Trials Bloomberg School of Public Health, Baltimore, MD, USA

    Curtis L. Meinert

Section Editor information

  1. Department of Medicine, University of Alabama, Birmingham, AL, USA

    O. Dale Williams

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Garrett-Mayer, E. (2020). Power and Sample Size. In: Piantadosi, S., Meinert, C. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_213-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52677-5_213-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52677-5

  • Online ISBN: 978-3-319-52677-5

  • eBook Packages: Springer Reference MathematicsReference Module Computer Science and Engineering

Publish with us

Policies and ethics

Search

Navigation